Medscape is available in 5 Language Editions – Choose your Edition here.


Acne Vulgaris

  • Author: Jaggi Rao, MD, FRCPC; Chief Editor: William D James, MD  more...
Updated: May 20, 2016

Practice Essentials

Acne vulgaris is a common chronic skin disease involving blockage and/or inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland). Acne can present as noninflammatory lesions, inflammatory lesions, or a mixture of both, affecting mostly the face but also the back and chest.[1] See the image below.

Acne, grade I; multiple open comedones. Acne, grade I; multiple open comedones.

Acne vulgaris has a multifactorial pathogenesis, of which the key factor is genetics.[2] Acne develops as a result of an interplay of the following four factors: (1) follicular epidermal hyperproliferation with subsequent plugging of the follicle, (2) excess sebum production, (3) the presence and activity of the commensal bacteria Propionibacterium acnes, and (4) inflammation.[3]

Signs and symptoms

Acne vulgaris is characterized by noninflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. Acne vulgaris typically affects the areas of skin with the densest population of sebaceous follicles (eg, face, upper chest, back). Local symptoms of acne vulgaris may include pain, tenderness, or erythema.

Systemic symptoms are most often absent in acne vulgaris. Severe acne with associated systemic signs and symptoms, such as fever, is referred to as acne fulminans. Severe acne, characterized by multiple comedones, without the presence of systemic symptoms, is known as acne conglobata. This severe form of acne frequently heals with disfiguring scars. Additionally, acne vulgaris may have a psychological impact on any patient, regardless of the severity or the grade of the disease.[4]

See Clinical Presentation for more detail.


Examination in patients with acne vulgaris includes the following features:

  • Comedonal acne: Presence of open and closed comedones but usually no inflammatory papules or nodules
  • Mild acne: Presence of comedones and a few papulopustules
  • Moderate acne: Presence of comedones, inflammatory papules, and pustules; a greater number of lesions are present than in milder inflammatory acne
  • Nodulocystic acne: Presence of comedones, inflammatory lesions, and large nodules greater than 5 mm in diameter; scarring is often evident

Laboratory tests

Acne vulgaris is a clinical diagnosis. However, laboratory testing may be indicated in the following situations:

  • Female patients with dysmenorrhea or hirsutism: Consider a hormonal evaluation with levels of total and/or free testosterone, dehydroepiandrosterone sulfate, luteinizing hormone, and follicle-stimulating hormone
  • Cases refractory to treatment or when improvement is not maintained: Culture skin lesions to rule out gram-negative folliculitis

See Workup for more detail.


Treatment of acne vulgaris should be directed toward the known pathogenic factors, including follicular hyperproliferation, excess sebum, P acnes, and inflammation. The most appropriate treatment is based on the grade and severity of the acne.


The following medications are used in the treatment of Propionibacterium acne vulgaris:

  • Retinoid-like agents (eg, topical tretinoin, adapalene, tazarotene, isotretinoin)
  • Antibiotics (eg, tetracycline, minocycline, doxycycline, trimethoprim/sulfamethoxazole, clindamycin, topical clindamycin, topical erythromycin, daptomycin)
  • Selective aldosterone antagonists (eg, spironolactone)
  • Estrogen/progestin combination oral contraceptive pills (eg, ethinyl estradiol, drospirenone, and levomefolate; ethinyl estradiol and norethindrone; ethinyl estradiol and norgestimate; ethinyl estradiol and drospirenone)
  • Acne products (eg, erythromycin and benzoyl peroxide, clindamycin and tretinoin, clindamycin and benzoyl peroxide, azelaic acid, benzoyl peroxide)

When a topical or systemic antibiotic is used, it should be used in conjunction with benzoyl peroxide or topical retinoid to reduce the emergence of resistance.


Diet therapy, such as a low-glycemic diet and avoidance of “junk foods,” has been suggested as a nonpharmacologic measure to manage acne vulgaris.


Procedural treatments for acne vulgaris include the following:

  • Manual extraction of comedones
  • Intralesional steroid injections
  • Superficial peels that use glycolic or salicylic acid

See Treatment, Guidelines, and Medication for more detail.



Acne vulgaris is characterized by noninflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. Acne vulgaris typically affects the areas of skin with the densest population of sebaceous follicles; these areas include the face, the upper part of the chest, and the back.

Acne vulgaris is the most common skin disease in the United States; it affects an estimated 80% of Americans at some time during their lives.[5] Twenty percent have severe acne, which can result in permanent physical and mental scarring.

Medscape Reference articles on acne include Acne Conglobata,Acne Fulminans,Acne Keloidalis Nuchae, and Acneiform Eruptions. Also see the Medscape Acne Resource Center.



The pathogenesis of acne vulgaris is multifactorial. The key factor is genetics.[2] Acne develops as a result of an interplay of the following four factors[3] :

  • Release of inflammatory mediators into the skin
  • Follicular hyperkeratinization with subsequent plugging of the follicle
  • Propionibacterium acnes follicular colonization
  • Excess sebum production

Research has shown that inflammatory responses actually occur before hyperkeratinization. Cytokines produced by CD4+ T cells and macrophages activate local endothelial cells to up-regulate inflammatory mediators such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and human leukocyte antigen (HLA)–DR in the vessels around the pilosebaceous follicle.[6]

Follicular hyperkeratinization involves increased keratinocyte proliferation and decreased desquamation, leading to sebum- and keratin-filled microcomedones.[7]

P acnes is an anaerobic organism present in acne lesions. The presence of P acnes promotes inflammation through a variety of mechanisms. P acnes stimulates inflammation by producing proinflammatory mediators that diffuse through the follicle wall. Studies have shown that P acnes activates the toll-like receptor 2 on monocytes and neutrophils.[8] Activation of the toll-like receptor 2 then leads to the production of multiple proinflammatory cytokines, including interleukins 12 and 8 and tumor necrosis factor. Hypersensitivity to P acnes may also explain why some individuals develop inflammatory acne vulgaris while others do not.[9]

Excess sebum is another key factor in the development of acne vulgaris. Sebum production and excretion are regulated by a number of different hormones and mediators. In particular, androgen hormones promote sebum production and release.[10] The degree of comedonal acne in prepubertal girls correlates with circulating levels of the adrenal androgen dehydroepiandrosterone sulfate (DHEA-S).[11]

Numerous other mediators and receptors, including growth hormone and insulinlike growth factor, as well as peroxisome proliferator-activated receptors also regulate the sebaceous gland and may contribute to the development of acne.[12, 13] Furthermore, the sebaceous gland acts a neuroendocrine-inflammatory organ that is activated via corticotrophin-releasing hormones in response to stress and normal functions.[14]



United States

Acne vulgaris affects 80% of Americans at some time during their lives.[5] Twenty percent have severe acne, which can result in permanent physical and mental scarring.


Persons of some races are affected more than others. Cystic acne is prevalent in the Mediterranean region from Spain to Iran.[15]


Acne is common in North American whites. African Americans have a higher prevalence of pomade acne, likely stemming from the use of hair pomades. Ethnicities with darker skin are also more prone to postinflammatory hyperpigmentation.[16]


During adolescence, acne vulgaris is more common in males than in females. In adulthood, acne vulgaris is more common in women than in men.[17]


Acne or acneform lesions, such as in neonatal cephalic pustulosis, may be present in the first few weeks and months of life, when a newborn is still under the influence of maternal hormones and when the androgen-producing portion of the adrenal gland is disproportionately large.[18] This neonatal acne tends to resolve spontaneously. However, some neonates may require therapy (eg, topical retinoids).[18]

Adolescent acne usually begins with the onset of puberty, when the gonads begin to produce and release more androgen hormone.

Acne is not limited to adolescence. Twelve percent of women and 5% of men at aged 25 years have acne. By age 45 years, 5% of both men and women still have acne.[19]



Acne may cause long-lasting and detrimental psychosocial and physical effects. It is associated with depression and anxiety, regardless of disease severity, although the psychological effects usually improve with treatment. Furthermore, acne may cause permanent scarring that is difficult to correct.[20]

In male patients, acne generally clears by early adulthood. Five percent of men still have acne at age 25 years. Female patients frequently have adult acne. Twelve percent of women still have acne at age 25 years. Five percent of women still have acne at age 45 years.[19]

The overall prognosis for persons with acne is good.


Patient Education

Patients should be instructed on their morning and evening treatment programs. Retinoid dermatitis may develop at approximately day 10 of therapy. Patients must be informed of this in advance so they will not consider this exfoliation an allergy. By skipping a day or 2 and restarting the program slowly, the skin can adapt to this irritation.

Prescriptions should be accompanied by a discussion of the potential adverse effects.

For patient education resources, see the Skin Conditions and Beauty Center as well as the patient education article Acne. Also see the Medscape Acne Resource Center.

Contributor Information and Disclosures

Jaggi Rao, MD, FRCPC Clinical Professor of Medicine, Division of Dermatology and Cutaneous Sciences, Director of Dermatology Residency Program, University of Alberta Faculty of Medicine and Dentistry

Jaggi Rao, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, Canadian Medical Association, Pacific Dermatologic Association, Royal College of Physicians and Surgeons of Canada, Canadian Medical Protective Association, Canadian Dermatology Association

Disclosure: Nothing to disclose.


Jennifer Chen University of Alberta Faculty of Medicine and Dentistry, Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Associate Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Joshua A Zeichner, MD Assistant Professor, Director of Cosmetic and Clinical Research, Mount Sinai School of Medicine; Chief of Dermatology, Institute for Family Health at North General

Joshua A Zeichner, MD is a member of the following medical societies: American Academy of Dermatology, National Psoriasis Foundation

Disclosure: Received consulting fee from Valeant for consulting; Received grant/research funds from Medicis for other; Received consulting fee from Galderma for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Pharmaderm for consulting; Received consulting fee from Onset for consulting.

  1. Dawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013 May 8. 346:f2634. [Medline].

  2. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol. 1999 Aug. 141(2):297-300. [Medline].

  3. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May. 60(5 Suppl):S1-50. [Medline].

  4. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999 Feb. 140(2):273-82. [Medline].

  5. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan. 58(1):56-9. [Medline].

  6. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003 Jul. 121(1):20-7. [Medline].

  7. Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988 May. 118(5):651-9. [Medline].

  8. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1. 169(3):1535-41. [Medline].

  9. Webster GF. Inflammatory acne represents hypersensitivity to Propionibacterium acnes. Dermatology. 1998. 196(1):80-1. [Medline].

  10. Pochi PE, Strauss JS. Sebaceous gland activity in black skin. Dermatol Clin. 1988 Jul. 6(3):349-51. [Medline].

  11. Lucky AW, Biro FM, Simbartl LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr. 1997 Jan. 130(1):30-9. [Medline].

  12. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006 Sep. 126(9):2002-9. [Medline].

  13. Smith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol. 2006 Jun. 126(6):1226-32. [Medline].

  14. Zouboulis CC, Böhm M. Neuroendocrine regulation of sebocytes -- a pathogenetic link between stress and acne. Exp Dermatol. 2004. 13 Suppl 4:31-5. [Medline].

  15. Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J Am Acad Dermatol. 2007 Aug. 57(2):247-56. [Medline].

  16. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010 Apr. 3(4):24-38. [Medline]. [Full Text].

  17. Shaw JC, White LE. Persistent acne in adult women. Arch Dermatol. 2001 Sep. 137(9):1252-3. [Medline].

  18. [Guideline] Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013 May. 131 Suppl 3:S163-86. [Medline].

  19. Kligman AM. Postadolescent acne in women. Cutis. 1991 Jul. 48(1):75-7. [Medline].

  20. Barnes LE, Levender MM, Fleischer AB Jr, Feldman SR. Quality of life measures for acne patients. Dermatol Clin. 2012 Apr. 30(2):293-300, ix. [Medline].

  21. Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol. 2010 Jun. 9(6):627-36. [Medline].

  22. Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception. 1996 Mar. 53(3):163-70. [Medline].

  23. Basler RS. Acne mechanica in athletes. Cutis. 1992 Aug. 50(2):125-8. [Medline].

  24. [Guideline] Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May. 74 (5):945-973.e33. [Medline].

  25. Cunliffe WJ, Holland DB, Jeremy A. Comedone formation: etiology, clinical presentation, and treatment. Clin Dermatol. 2004 Sep-Oct. 22(5):367-74. [Medline].

  26. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul. 49(1 Suppl):S1-37. [Medline].

  27. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008. 9(6):369-81. [Medline].

  28. Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg. 2008 Sep. 27(3):177-82. [Medline].

  29. Cunliffe WJ, Holland KT. The effect of benzoyl peroxide on acne. Acta Derm Venereol. 1981. 61(3):267-9. [Medline].

  30. Eady EA, Jones CE, Gardner KJ, Taylor JP, Cove JH, Cunliffe WJ. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993 May. 128(5):556-60. [Medline].

  31. Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol. 2008 Dec. 7(12):1149-52. [Medline].

  32. Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 1996 Nov. 38(5):829-37. [Medline].

  33. Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, Acne, and Staphylococcus aureus Colonization. Arch Dermatol. 2011 Aug. 147(8):917-21. [Medline].

  34. Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology. 1993. 187(3):193-6. [Medline].

  35. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000 Jan. 39(1):45-50. [Medline].

  36. Koulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis. 2000 Oct. 66(4):281-6. [Medline].

  37. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000 Sep. 43(3):498-502. [Medline].

  38. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs. 1984 Jul. 28(1):6-37. [Medline].

  39. Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of Conventional, Low-dose and Intermittent Oral Isotretinoin in the Treatment of Acne: A Randomized, Controlled Comparative study. Br J Dermatol. 2010 Nov 29. [Medline].

  40. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998 Mar. 134(3):376-8. [Medline].

  41. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011 Feb. 131(2):363-70. [Medline].

  42. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link?. J Am Acad Dermatol. 2001 Nov. 45(5):S168-75. [Medline].

  43. Bagatin E, dos Santos Guadanhim LR, Yarak S, Kamamoto CS, de Almeida FA. Dermabrasion for acne scars during treatment with oral isotretinoin. Dermatol Surg. 2010 Apr. 36(4):483-9. [Medline].

  44. Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. Br J Dermatol. 2000 May. 142(5):855-6. [Medline].

  45. Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA. 1969 Dec 15. 210(11):2071-4. [Medline].

  46. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol. 1996 Aug. 132(8):934-9. [Medline].

  47. [Guideline] American Academy of Dermatology. Ten Things Physicians and Patients Should Question. Choosing Wisely. April 30, 2016. Available at August 19, 2015;

  48. [Guideline] Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, et al. Management of acne: Canadian clinical practice guideline. CMAJ. 2015 Nov 16. [Medline]. [Full Text].

  49. Harding A. Canadian dermatologists issue new acne treatment guidelines. Reuters Health Information. Available at November 18, 2015; Accessed: December 11, 2015.

  50. FDA safety alert. Over-The-Counter Topical Acne Products: Drug Safety Communication - Rare But Serious Hypersensitivity Reactions. U.S. Food and Drug Administration. Available at Accessed: June 30, 2014.

Acne, grade I; multiple open comedones.
Acne, grade II; closed comedones.
Acne, grade III; papulopustules.
Acne, grade IV; multiple open comedones, closed comedones, and papulopustules, plus cysts.
Acne with reactive hyperpigmentation; before treatment.
Acne with reactive hyperpigmentation; after treatment.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.